Disease · MONDO_0002041

fungal infectious disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. fungal infectious disease. Diseases, record MONDO_0002041. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002041

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: fungal infectious disease; Open Targets
Open Targets ID: MONDO_0002041; Open Targets
Other names: Fungi caused disease or disorder, Fungi disease or disorder, Fungi infection, Fungi infectious disease, mycosis; Open Targets
Disease Ontology: DOID:1564; Disease Ontology
MeSH: D009181; MeSH
NCI Thesaurus: C3245; NCI Thesaurus
Highest stage of its drugs: Approval, for 10 of its 14 drugs, from DailyMed and PMDA; Open Targets

Drugs14

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
POSACONAZOLE	CHEMBL1397	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
AMPHOTERICIN B	CHEMBL267345	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
CLOTRIMAZOLE	CHEMBL104	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
ITRACONAZOLE	CHEMBL64391	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
METHOTREXATE SODIUM	CHEMBL3244648	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
CASPOFUNGIN ACETATE	CHEMBL5314378	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
METHYLPREDNISOLONE ACETATE	CHEMBL1364144	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
MICONAZOLE	CHEMBL91	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
VINBLASTINE SULFATE	CHEMBL378544	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets

1 to 10 of 14

See all 14 drugs

Targets17

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Approval	https://conductscience.org/library/genes/1719	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	1	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	1	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	1	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	1	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	1	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	1	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/81027	Drugs and targets

1 to 10 of 17

See all 17 targets

Trials2

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04240886	Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds	Phase 2	21	2023-05-19	Invasive Fungal Infections	FOSMANOGEPIX	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT04665037	Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)	Phase 2	40		Invasive Fungal Infection	POSACONAZOLE	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
40203286	RESULT	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002041

GET https://conductscience.org/api/diseases/v1/MONDO_0002041/drugs

API reference For AI assistants